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Abstract
The lack of BTK in X-linked agammaglobulinemia (XLA) patients does not affect monocytes
and polymorphonuclear cells (PMN) phenotype and functions. In this study, we show that
XLA patients had an increased frequency of the intermediate monocytes subset and that
BTK-deficient monocytes and PMN had a normal expression of receptors involved in the
activation and cellular responses. We demonstrate that BTK is not required for migration,
phagocytosis and the production of reactive oxygen species (ROS) following engagement
of FC gamma receptors (FcγR). XLA monocytes and PMN showed an efficient calcium
(Ca2+)-independent activation of oxidative burst, suggesting that oxidative burst is less
dependent by Ca2+ mobilization. The phagocytosis was functional and it remained unaltered
also after Ca2+ chelation, confirming the independence of phagocytosis on Ca2+ mobiliza-
tion. Intravenous immunoglobulin (IVIg) infusion exerted an anti-inflammatory effect by
reducing the frequency of pro-inflammatory monocytes. In monocytes, the IVIg reduce the
oxidative burst and phagocytosis even if these functions remained efficient.
Introduction
X-linked agammaglobulinemia (XLA) is a symptomatic primary antibody deficiency (PAD)
caused by mutations in the Bruton’s tyrosine kinase (BTK) gene located on the long arm of X-
chromosome encoding the cytoplasmic BTK [1, 2]. These mutations lead to the nearly com-
plete arrest of B cell differentiation in the bone marrow at the pre-B cell stage resulting in
absent or very low peripheral B cells, agammaglobulinemia, absence of B cell-dependent lym-
phoid tissues and inability to mount specific antibody responses [3–5]. BTK is involved in reg-
ulation of proliferation, differentiation and survival of B cells and in functions of innate
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immune cells, as shown by the altered innate immune responses observed in monocytes, den-
dritic cells (DC) and neutrophils of XLA patients [6–9]. BTK is a mediator acting downstream
the spleen tyrosine kinase (Syk), a cytoplasmic protein-tyrosine kinase member of Src family
of non-receptor tyrosine kinases. BTK is normally activated by a variety of receptors, included
Fc gamma receptors (FcγR). The antigen engagement of the FcγRs is able to induce the activa-
tion of Syk [10–12] that consequently activates the axis BTK-PLCγ2/Ca2+ signaling pathway
[13, 14].
XLA patients develop during the first year of life recurrent bacterial infections, mostly in
the respiratory tract, gastrointestinal tract and skin [15, 16]. Beside the absence of B cells, XLA
patients occasionally present neutropenia suggesting a potential neutrophil dysfunction [17],
as also demonstrated in the mouse model of XLA [18]. The standard therapy in XLA is the
administration of human polyvalent immunoglobulins G (IgG) [19, 20] that beside their anti-
body replacement activity have been shown to modulate innate immune cells [21, 22]. We
have previously shown that in patients affected by a different PAD entity, the Common Vari-
able Immune Disorders (CVID) [23], the IgG administration reduced the overexpression of
CD11b and of sialic acid-binding immunoglobulin-like lectin receptor (Siglec 9) on monocytes
and the frequency of peripheral pro-inflammatory monocytes. The expansion of pro-inflam-
matory monocytes has been observed also in other systemic inflammatory diseases [24, 25]
together with an overexpression of CD11c, a receptor involved in adherence and phagocytosis
[26, 27]. In XLA patients, we evaluated the expression of CD181, CD66b, CD11b, CD11c,
CD16 and Siglec 9 receptors on unstimulated and E. coli-stimulated monocytes and PMN.
CD181 (also called CXCR1) is a surface receptor for IL-8, a primary chemo-attractant involved
in innate immune cells activation [28]. CD66b is exclusively expressed on human granulocytes
and it is recognized as a granulocyte activation marker, involved in neutrophils adhesion,
migration and pathogen binding [29, 30]. CD11b is a component of the phagocytic receptor
αMβ2 (or CD11b/CD18) involved in phagocytosis, expressed on human PMN, NK cells and
mononuclear phagocytes. Siglec 9 is a member of transmembrane sialic acid-binding proteins
CD33-related [31, 32] with a postulated inhibitory activity on the immune response through
host and bacterial sialoglycans recognition [33, 34]. The simultaneous expression of CD11b
and Siglec 9 might play a pivotal role in monocytes activity [23]. CD11c is an integrin mole-
cule, which is a member of αXβ2 receptor that overlap the properties of αMβ2 integrin
involved in adherence and phagocytosis of complement coated particles [26, 27]. The clear-
ance of invading microorganisms by innate immune cells constitutes an essential arm of host
defense. The entire process can be separated in several stages: adhesion, migration into
inflamed tissues, phagocytosis and oxidative burst. Since Ca2+ mobilization is involved in ROS
production through the axis BTK-PLCγ2, induced by FcγR clustering [35, 36], it is possible
that the BTK mutation in XLA patients could affect the calcium flux from internal storage,
impairing the ROS production. Thus, we verified if the lack of BTK kinase activity affect
monocytes and PMN phagocytosis, oxidative burst and Ca2+ mobilization. In addition, since
BTK is involved in degranulation and in FcγR-mediated cytokine production [36], we ana-
lyzed additional PMN functions that might be impaired in XLA including IL-8 production
and elastase release. Finally, PMN and monocytes frequencies and functions were analyzed ex
vivo shortly after intravenous IgG (IVIg) infusions administered at replacement dosages.
Materials and methods
Patients and controls
XLA was diagnosed according to the International Union of Immunological Societies Expert
Committee for Primary Immunodeficiency criteria [37]. Six adult XLA patients (age range of
In vivo effects of IVIg infusion on innate immune cells of XLA
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20–60 years; mean age: 36.7 ± 15.4 years) and ten age-matched male healthy donors (HD) (age
range of 27–58 years; mean age: 39.6 ± 9.8 years) were enrolled for the study. All XLA patients
were on replacement treatment, with a cumulative monthly dosage of 400–600 mg/kg of IVIg
administered every three weeks (S1 Table). The infusion time ranged from 2 to 3 hours. The
infusion speed was established according to the individual tolerability. This study was
approved by the Ethics Committee of the Sapienza University of Rome. All participants gave
written informed consent prior to inclusion.
Blood samples preparation
Heparinized whole blood samples were collected from 10 HD and 6 XLA patients immediately
before and one hour after IVIg administration. These time points were chosen based on our
previous observations [23, 38], taking into consideration that the highest increase of several
cytokines plasma concentration occurs within one hour after IVIg infusion [39]. Total periph-
eral blood monocytes and neutrophils count were determined from blood cell counts and
white blood cell differentials. For evaluating circulating cell without the harm of cell loss
related to the density gradient centrifugation procedure, peripheral red blood cells was lysed
using lysing buffer (Becton Dickinson, BD). Samples were washed twice before staining with
various combinations of fluorochrome-labeled antibodies. All antibodies were obtained from
BD Biosciences. Flow cytometric analysis was done with a FACSCalibur instrument (BD)
using CellQuest (BD) and FlowJo (TreeStar, Ashland, Ore) software. The cytometer stability
and sensitivity were checked before each acquisition session by using microbeads designed to
control the efficiency, the coefficient of variation of scatter and fluorescence signals and the
time delay calibration (Nile Red Fluorescent particles and Calibrite APC Beads, all from BD).
Results were expressed as geometric mean Fluorescence Intensity (MFI) of any given marker
within the defined population. 30.000 events were counted per sample.
Phenotypic analysis of monocyte subpopulations
Whole blood samples were first treated to lyse red blood cells and then washed twice and
stained at 4˚C for 30 min with combinations of fluorochrome-labeled antibodies. Samples
were washed, suspended in ice cold PBS and analyzed by a 4-color flow cytometry single plat-
form. Monocytes subpopulations were phenotypically selected by gating on CD14+ HLA-DR+
monocytes and then classified according to their expression of CD14 and CD16 into classical
(CD14++CD16-), intermediate (CD14++CD16+) and non classical monocytes (CD14+CD16++).
An isotype control (IgG1, BD) with the same fluorochrome of CD16 antibody was run in paral-
lel in order to set the boundary between classical and intermediate monocytes [23]. The surface
expression of CD181, CD11b, CD11c and Siglec 9 receptors was evaluated on monocytes sam-
ples from erythrocytes-lysed whole blood, performing a staining at 4˚C for 30 min with combi-
nations of fluorochrome-labeled antibodies. In parallel, we used an isotype control (IgG1, BD)
for each receptor analyzed. Results were expressed as percentage of cells that stained positive
for a given marker.
Analysis of receptors expression on PMN
The expression of CD181, CD66b, CD11b, CD11c, CD16 and Siglec 9 was evaluated on PMN
samples from erythrocytes-lysed whole blood, performing a staining at 4˚C for 30 min with
combinations of fluorochrome-labeled antibodies. Samples were washed, suspended in ice
cold PBS and analyzed by flow cytometry. PMN were identified by forward scatter (FSC) and
side scatter (SSC) characteristics (Panels A and B in S1 Fig).
In vivo effects of IVIg infusion on innate immune cells of XLA
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Monocytes and PMN stimulation by Escherichia coli
One hundred μL of whole blood were added to 20 μl of pre-cooled opsonized not labeled
whole Escherichia coli (E. coli) at a concentration of 1-2x109/ml (Glycotope, Biotechnology).
Samples were incubated in water bath for 20 min at 37˚C and erythrocytes were lysed for 15
min at room temperature. Cells stimulated were stained at 4˚C for 30 min with fluorochrome-
labeled antibodies in various combinations to evaluate the receptors expression.
Monocytes and PMN oxidative burst activity
The leukocyte oxidative burst was analyzed by using the PHAGOBURST assay (Glycotope,
Biotechnology). Whole blood samples (100 μl) were incubated in a water bath for 20 min at
37˚C with opsonized E. coli (1-2x109/ml), PMA (1.62 mM) and wash solution as negative con-
trol. The percentage and MFI of cells that produced ROS was analyzed. The intracellular pro-
duction of superoxide anions and hydrogen peroxide in monocytes and PMN in response to
phagocytosis of bacteria was tested by using the fluorescence probes dihydrorhodamine 123
(DHR 123). We repeated the analysis of the oxidative burst using non-opsonized E. coli
(1.5x109/ml) as control in order to exclude the FcγR-independent phagocytosis. In parallel, we
performed the study of oxidative burst by using BAPTA-AM (Unimed Scientifica) as calcium
chelator, in order to verify the Ca2+-dependence production of ROS triggered by FcγR stimula-
tion. Whole blood samples were pre-treated with 100 μM of BAPTA-AM for 30 min and then
they were incubated in a water bath for 20 min at 37˚C with opsonized E. coli (1-2x109/ml).
The oxidation lead to fluorescence detected by flow cytometry, by using the blue-green excita-
tion light (488 nm argon-ion laser).
Monocytes and PMN phagocytosis
The leukocyte phagocytosis was determined by using a PHAGOTEST assay (Glycotope, Bio-
technology). Whole blood samples (100 μl) were incubated in a water bath for 10 min at 37˚C
with opsonized FITC-labeled E. coli (2x109/ml). As negative controls, 100 μl of each sample
were incubated in an ice bath for 10 min with opsonized FITC-labeled E. coli (2x109/ml). As
control, the same experiment was done by using non opsonized FITC-labeled E. coli (2x109/
ml). The percentage and MFI of granulocytes and monocytes having performed phagocytosis
was analyzed. In parallel, we tested the effect of calcium chelator on phagocytosis in order to
confirm the Ca2+-independence of the process. Whole blood samples were pre-treated with
100 μM of BAPTA-AM for 30 min and then incubated in a water bath for 10 min at 37˚C with
FITC-labeled E. coli (2x109/ml). Cells were analyzed by flow cytometry by using the blue-green
excitation light (488 nm argon-ion laser).
PMN migration
PMN chemotaxis was determined by the MIGRATEST CHEMOTAXIS assay (Glycotope, Bio-
technology). Heparinized whole blood samples (1000 μl) were added to leukocyte separation
medium for isolation of leukocyte-rich plasma (LRP), for 40 min at room temperature. After
isolation, 100 μl of LRP were added into cell culture insert (3.0 μm pore size) and incubated in
a water bath for 30 min at 37˚C with chemotactic peptide N-formyl-Met-Leu-Phe (fLMP).
After incubation, the cell suspensions were added in two separate tubes and placed on ice.
20 μl of cell suspension from the cell culture insert of the negative control were mixed with
180 μl of incubation buffer and then transferred on a third tube. 20 μl of antibody and count-
ing reagent were added to LRP and incubated for 10 min in an ice bath in the dark. Finally,
20 μl of vital DNA staining solution were added per tube and incubated 5 min on ice. The
In vivo effects of IVIg infusion on innate immune cells of XLA
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number of migrated PMN was analyzed by flow cytometry by using the blue-green excitation
light (488 nm argon-ion laser).
PMN elastase assay
The PMN elastase was quantified by Human PMN Elastase Platinum ELISA (Affymetrix
eBioscience). 100 μl of each plasma sample were added to a microwell plate coated with poly-
clonal antibody to human PMN elastase and incubated at room temperature for 1 hour. After
washing, samples were incubated with TMB Substrate Solution at room temperature for 20
min in the dark. 50 μl of stop solution were added to stop the reaction. The absorbance was
determined at 450 nm on a microplate reader (Multiskan™ FC Microplate Photometer,
Thermo Scientific). Concentrations were expressed as ng/ml.
IL-8 plasma dosage
Interleukin-8 (IL-8) was measured by using a commercially available kit ELISA (CliniS-
ciences). Plasma was collected from blood samples unstimulated and stimulated with E. coli by
centrifugation for 15 min at 1000 x g, diluted and tested in duplicates.
100 μl of each plasma sample were added to a microwell plate coated with monoclonal anti-
body to human IL-8 and incubated at 37˚C for 90 min. After washing, samples were incubated
with Biotin-Conjugate Solution at 37˚C for 1 h. Then, each well was washed several times and
incubated with 100 μl of Streptavidin-HRP at 37˚C for 30 min. After washing, 100 μl of Sub-
strate Solution were added to each well and incubated for 10–20 min a 37˚C. 100 μl of stop
solution were added to stop the reaction. The absorbance was determined at 450 nm on a
microplate reader (Multiskan™ FC Microplate Photometer, Thermo Scientific). Concentra-
tions were expressed as pg/ml.
Statistical analysis
Data were analyzed using the Mann-Whitney U test for unpaired two groups or by paired Wil-
coxon test. Correlations were calculated by means of linear regression analysis.
Data were analyzed with StatView 5.0.1 software (SAS Institute, Cary, NC). A p value equal
or less than 0.05 was considered as statistically significant.
Results
Monocyte subsets
Monocytes subsets were identified according to their expression CD14 and the CD16 (Fig 1A
and 1B). Absolute counts of peripheral blood total monocytes, classical and non classical
monocytes did not show any difference between XLA and HD. Classical and non classical
monocyte were similarly represented in XLA and HD while the frequency of intermediate
monocytes was increased in XLA (Fig 1C). In Fig 1D we show the increase of monocytes sub-
sets from XLA patients compared to HD expressed as percentage.
After IVIg, the frequency of intermediate monocytes rapidly decreased remaining higher
than HD (Fig 1C and 1D) while the frequency of non classical and classical monocyte subsets
did not change (Fig 1C).
Receptors expression
Monocytes. We evaluated the surface expression of CD181, CD11b, CD11c and Siglec 9
receptors involved in the regulation of monocytes function. As shown in Table 1, we found
that all receptors were expressed at a similar level in the three monocytes subsets in XLA
In vivo effects of IVIg infusion on innate immune cells of XLA
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patients and HD. Moreover, IVIg administration did not induce any variation of their expres-
sion (Fig 2A and 2D). The stimulation with opsonized E. coli induced an increase of all recep-
tors similarly in XLA patients and HD (Table 1). This overexpression induced by E. coli was
preserved after IVIg, showing that IVIg replacement did not affect the monocytes ability to
respond to opsonized bacteria (Table 1).
PMN. The activation status of PMN strongly influence the respiratory burst, phagocytosis
and adhesion processes. As shown in Fig 3A and 3F and in Table 2, PMN from XLA and HD
showed an overlapping expression of all receptors with the exception of CD66b that was over-
expressed in XLA patients (Fig 3B). However, this increase was not correlated with a physio-
logical dysfunction, as demonstrated by the normal PMN ability to release elastase, a
proteinase needed to degrade foreign organisms and host tissue during inflammation. In fact,
at baseline, the elastase release was similar in XLA and HD (Fig 4A and 4B). After E. coli stimu-
lation, the elastase release rapidly increased in XLA and in HD. After IVIg infusion, PMN
maintained their degranulation ability (Fig 4B).
Fig 1. Frequencies of non classical, intermediate and classical monocytes increased from XLA patients before and after IVIg
infusion respect to HD. (A and B) Monocytes subpopulations were phenotypically classified according to their expression of CD14 and
CD16 into classical (CD14++CD16-), intermediate (CD14++CD16+) and non classical monocytes (CD14+CD16++) in a representative XLA
patient before and after IVIg infusion. Percentages denote mean values. (C) Histograms show that non classical and classical monocyte
frequencies from XLA patients are similar to that observed on HD and that IVIg infusion did not change their frequency. Intermediate
monocytes percentage is increased in XLA patients (▪p = 0.01), IVIg infusion induce their reduction (▪▪p = 0.04) even if remained at
higher level respect to HD (▪▪▪p = 0.01). (D) Histograms denote the percentage of increase of the three monocytes subsets of XLA
patients respect to HD. Histograms denote mean values and bars standard deviation. Statistical significance as determined by the
nonparametric Mann Whitney and Wilcoxon Signed Rank test is indicated as p value.
https://doi.org/10.1371/journal.pone.0175961.g001
Table 1. Receptors expression on monocytes subsets from HD and XLA patients.
HD XLA before IVIg XLA after IVIg
Receptor Non classical Intermediate Classical Non classical Intermediate Classical Non
classical
Intermediate Classical
CD181
(MFI)
UN 7.1 ± 1 9.8 ± 2.6 9.6 ± 1.7 6.2 ± 0.8 11.5 ± 2.4 11.4 ± 2.5 6.1 ± 0.9 9.7 ± 2.5 10.1 ± 1.9
ST 22.3 ± 1.5 15.2 ± 3.6 15.6 ± 1.4 18.6 ± 1.4 17.2 ± 3.5 17.8 ± 2.7 18.4 ± 1.9 13.9 ± 4.7 15.1 ± 2.2
CD11b
(MFI)
UN 3 ± 2.4 30.1 ± 8.5 38.1 ± 12.7 4 ± 2.7 23.4 ± 8.3 40.7 ± 12.4 5.9 ± 2.3 29.2 ± 7.2 48.4 ± 9.4
ST 8.6 ± 4 72.8 ± 9.8 96.7 ± 12.1 9 ± 6.6 62 ± 25.2 75.5 ± 18.8 14.1 ± 8.6 70.3 ± 27 75.4 ± 26.1
CD11c
(MFI)
UN 40.2 ± 19.3 59.9 ± 24.3 48.8 ± 14.8 56 ± 22.4 62.4 ± 5.4 50.2 ± 10 52.7 ± 23.7 65.7 ± 21.4 38.4 ± 7.7
ST 128.5 ± 10.6 117.3 ± 21.8 101.4 ± 9.5 140.5 ± 0.7 120.5 ± 2.1 111.5 ± 0.7 141 ± 9.9 112 ± 15.6 107 ± 14.1
Siglec 9
(MFI)
UN 83.3 ± 35.5 113.3 ± 28.1 103.2 ± 24.5 85.8 ± 8.4 129.6 ± 13.7 118 ± 17.2 88 ± 7.4 120.2 ± 10.5 106.3 ± 15.9
ST 102.2 ± 42.6 151.6 ± 38.4 146.5 ± 38.4 138.9 ± 56.5 151.5 ± 22.6 177.8 ± 55.2 96.8 ± 24.2 143.6 ± 27 143.5 ± 34.9
Values are expressed as Mean Fluorescence Intensity (MFI). UN: Unstimulated; ST: Stimulated with E. coli.
https://doi.org/10.1371/journal.pone.0175961.t001
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Moreover, also the PMN migration induced by fMLP was comparable in XLA patients and
HD. After IVIg, the PMN migration remained unaltered (Fig 5A and 5D). Thus, the explana-
tion for the increased CD66b remained obscure.
E. coli stimulation induced an overexpression of all receptors in XLA patients and HD, with
the exception of CD181, that was reduced, in line with a previous study [28].
After IVIg infusion, the expression of all receptors in unstimulated conditions and their
overexpression induced by E. coli remained unaltered, demonstrating that IVIg did not influ-
ence the phenotype of PMN, as previously shown in CVID patients [38] and did not affect the
PMN ability to respond to opsonized bacteria (Table 2).
IL-8 production
IL-8 plasma levels were similar in XLA (16.3 ± 5.7 pg/ml) and HD (17 ± 7.2 pg/ml) (Fig 6A).
After IVIg infusion, IL-8 levels remained unchanged (11.6 ± 3 pg/ml) (Fig 6B). After E. coli
Fig 2. CD181, CD11b, CD11c and Siglec 9 expression on monocytes subsets from HD and XLA patients before and after IVIg
infusion. Whole blood samples were analyzed for the expression of CD181, CD11b, CD11c and Siglec 9 before and after IVIg infusion.
The expression of all surface receptors was evaluated by performing a staining at 4˚C for 30 min with specific fluorochrome-labeled
antibody. Samples were washed, suspended in ice-cold PBS and analyzed by flow cytometry. XLA patients show a similar CD181,
CD11b, CD11c and Siglec 9 expression on monocytes subsets compared to HD. After IVIg infusion the expression of all receptors on
monocytes subsets remained unaltered. Results are expressed as Mean Fluorescence Intensity. Histograms denote mean values and
bars standard deviation.
https://doi.org/10.1371/journal.pone.0175961.g002
In vivo effects of IVIg infusion on innate immune cells of XLA
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stimulation, IL-8 increased in XLA (99.5 ± 53.1 pg/ml) and HD (107 ± 48.4 pg/ml). After IVIg
infusion, the E. coli-induced IL-8 production remained high (88.2 ± 42.4). Only one XLA
patient with a severe inflammatory condition had a very high IL-8 plasma levels (112 pg/ml
before IVIg and 94.6 pg/ml after IVIg) (Fig 6A and 6B). The same patient exhibit high level of
IL-8 after E. coli stimulation (before IVIg: 273.2 pg/ml; after IVIg: 277.8 pg/ml). This high IL-8
production was associated in the same patient with a high PMN elastase release (850 ng/ml).
Fig 3. CD181, CD11b, CD11c and Siglec 9 expression on PMN from HD and XLA patients before and after IVIg infusion. Whole
blood samples were analyzed for the expression of CD181, CD66b, CD11b, CD11c, CD16 and Siglec 9 before and after IVIg infusion.
The expression of all surface receptors was evaluated by performing a staining at 4˚C for 30 min with specific fluorochrome-labeled
antibody. Samples were washed, suspended in ice-cold PBS and analyzed by flow cytometry. XLA patients and HD show a similar
CD181, CD11b, CD11c, CD16 and Siglec 9 expression, while CD66b expression was higher on PMN from XLA patients compared to HD
(▪p = 0.001). After IVIg infusion, the expression of all receptors remained unaltered. Results are expressed as Mean Fluorescence
Intensity. Histograms denote mean values and bars standard deviation. Statistical significance, determined by the nonparametric Mann
Whitney test, is indicated as p value.
https://doi.org/10.1371/journal.pone.0175961.g003
Table 2. Receptors expression on PMN from HD and XLA patients.
HD XLA before IVIg XLA after IVIg
Receptor Unstimulated MFI Stimulated MFI Unstimulated MFI Stimulated MFI Unstimulated MFI Stimulated MFI
CD181 337.3 ± 16.8 205.8 ± 102.9* 361.5 ± 57.3 198 ± 76.5** 317.5 ± 98.3 169 ± 69.3**
CD66b 333.5 ± 29 1310 ± 162.6* 484.7 ± 66 1365.7 ± 287.7** 486.7 ± 116.4 1240 ± 654**
CD11b 20.7 ± 5.7 50.6 ± 0.8* 28.7 ± 9.4 49.3 ± 22.7** 24.8 ± 4.5 51.3 ± 29.5**
CD11c 20 ± 7.7 48.7 ± 11* 24.8 ± 10.5 50.4 ± 14.4** 24.4 ± 10.6 47.9 ± 13.6**
CD16 3555.6 ± 1144.5 4336.6 ± 1539.5* 3012 ± 952.8 3758.8 ± 1035.2** 2753.8 ± 794.4 3594.6 ± 1033.6**
Siglec 9 56.1 ± 15.5 99 ± 38.7* 61.7 ± 11.9 97.2 ± 27.4** 61.2 ± 16.1 81.7 ± 28.1**
Values are expressed as Mean Fluorescence Intensity (MFI).
* p 0.005,
** p 0.03
https://doi.org/10.1371/journal.pone.0175961.t002
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PLOS ONE | https://doi.org/10.1371/journal.pone.0175961 April 19, 2017 8 / 21
Fig 4. PMN elastase release. The PMN elastase was quantified by ELISA. Plasma samples were added to a
microwell plate coated with polyclonal antibody to human PMN elastase and incubated for 1 hour. (A) Data
show that, at baseline, the elastase release was similar in XLA and HD and that after E. coli stimulation, it
rapidly increased. (B) After the IVIg infusion, PMN maintained their degranulation ability. Only one patient
showed a high PMN elastase release, at baseline (gold). Concentrations were expressed as ng/ml.
•p = 0.028; ••p = 0.027.
https://doi.org/10.1371/journal.pone.0175961.g004
In vivo effects of IVIg infusion on innate immune cells of XLA
PLOS ONE | https://doi.org/10.1371/journal.pone.0175961 April 19, 2017 9 / 21
Phagocytosis
Phagocytosis contributes to the first line of defense against infection trough the engulfment
and destruction of invading microorganisms. It also plays a key role in tissue homeostasis and
remodeling.
Monocytes. Monocytes phagocytosis in XLA was normal at baseline (Fig 7A), but it was
decreased about 25% after IVIg (Fig 7A). The phagocytosis induced by a non-opsonized E. coli
was similar to the negative control confirming that E. coli was internalized through a FcγR
pathway.
PMN. PMN from XLA displayed a normal phagocytosis (Fig 7B). After IVIg, it remained
unaltered (Fig 7B), demonstrating that IVIg administered at replacement dosage did not affect
the ability of PMN to perform an efficient phagocytosis. Also in PMN, we found that phagocy-
tosis using non-opsonized E. coli was negligible.
Oxidative burst
The oxidative burst reflects the killing ability of innate immune cells and it involves many cel-
lular pathways. The lack of BTK activity might influence the respiratory burst, a process
requiring Ca2+ mobilization from internal storage. We verified this hypothesis on monocytes
and neutrophils subsets.
Monocytes. The monocytes ROS production after stimulation with opsonized E. coli or
PMA was comparable in XLA and HD (Fig 8A and 8B). After IVIg infusion, the oxidative
burst induced by E. coli slightly decreased about 13%, while it remained unaltered when PMA
was used as stimulus (Fig 8A and 8B). As control, we analyzed the oxidative burst using non-
opsonized E. coli in order to evaluate the oxidative burst resulting from the FcγR-independent
phagocytosis. As expected, we found that the oxidative burst was comparable to negative con-
trol, confirming that opsonized E. coli induced the oxidative burst through a FcγRs pathway.
The positive correlation between oxidative burst and phagocytosis (Panels A and B in S2 Fig)
confirmed the dependence of oxidative burst process from phagocytosis [40–43].
PMN. The PMN ROS production after E. coli and PMA stimulation was comparable in
XLA patients and HD (Fig 8C and 8D). After IVIg, the E. coli-induced and PMA-induced ROS
Fig 5. PMN migration. The quantitative determination of PMN chemotaxis was observed by incubating heparinized whole blood
samples on leukocyte separation medium for isolation of leukocyte-rich plasma (LRP). After isolation, LRP were incubated in a water
bath for 30 min at 37˚C with fLMP. Values are expressed as number of PMN which have migrated by flow cytometry. (A) Data show that
PMN migration induced by fMLP was comparable in XLA patients and HD. (A) After IVIg, the PMN migration remained unaltered.
Histograms denote mean values and bars standard deviation. (B, C and D) An example of the FACS analysis of PMN migration of a
representative XLA patient before and after IVIg infusion. The migrated cells were gated and analyzed within the quadrants of the dot
plots.
https://doi.org/10.1371/journal.pone.0175961.g005
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Fig 6. Plasma levels of IL-8 in XLA patients and HD. IL-8 production was measured by using a kit ELISA.
IL-8 plasma levels were similar in XLA and HD. (A) After E. Coli stimulation, IL-8 increased in XLA and HD. (B)
After IVIg infusion, IL-8 levels remained unchanged and the level after E. coli stimulation was well preserved.
Data show that only one XLA patient (gold) with a severe inflammatory condition had a very high IL-8 plasma
levels. The same patient exhibited high level of IL-8 after E. Coli stimulation. Concentrations were expressed
as pg/ml. *p = 0.042; **p = 0.043.
https://doi.org/10.1371/journal.pone.0175961.g006
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production remained unchanged (Fig 8C and 8D). The PMN oxidative burst induced by non-
opsonized E. coli was negligible.
All our observations were done in XLA patients under IVIg treatment since many years
and thus an interference of this chronic treatment on our data could not be ruled out. In order
to verify our findings, we analyzed a newly diagnosed untreated XLA patient (XLA naïve). We
found that XLA naïve patient showed receptors expression, migration, phagocytosis and oxi-
dative burst functions similar as XLA patients under chronic IVIg replacement.
Fig 7. Monocytes and PMN phagocytosis in XLA patients and HD. The quantitative determination of
leukocyte phagocytosis was tested by incubating whole blood samples in a water bath for 10 min at 37˚C with
FITC-labeled E. coli (2x109/ml). The percentage of cells having performed phagocytosis was analyzed as
number of ingested bacteria and results were expressed as Mean Fluorescence Intensity. XLA patients show
a similar monocytes phagocytosis compared to HD. (A) After IVIg administration monocytes phagocytosis
decreased (▪p = 0.04). XLA patients show a similar PMN phagocytosis compared to HD. (B) After IVIg
administration PMN phagocytosis remains unchanged. Histograms denote mean values and bars standard
deviation. Statistical significance, determined by the nonparametric Wilcoxon Signed Rank test, is indicated
as p value.
https://doi.org/10.1371/journal.pone.0175961.g007
Fig 8. Monocytes and oxidative burst in XLA patients and HD. The quantitative evaluation of leukocyte oxidative burst was observed
by incubating whole blood samples in a water bath at 37˚C with opsonized E. coli (1-2x109/ml) or PMA (1.62mM). The conversion of DHR
123 to R 123 were used to evaluated the intracellular ROS production. (A and B) XLA patients show a similar monocytes E. coli-induced
and PMA-induced oxidative burst compared to HD. (C and D) XLA patients show a comparable PMN E. coli-induced and PMA-induced
oxidative burst to HD. After IVIg, monocyte E. coli-induced oxidative burst slightly decreased (▪p = 0.004), but it remain unaltered when
PMA was provided. After IVIg, PMN ROS production remain unaltered. Results are expressed as Mean Fluorescence Intensity.
Histograms denote mean values and bars standard deviation. Statistical significance, determined by the nonparametric Wilcoxon Signed
Rank test, is indicated as p value.
https://doi.org/10.1371/journal.pone.0175961.g008
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Calcium chelation
The observation that BTK is not essential for the ROS production and that ROS production
requires Ca2+ mobilization [44, 45] prompted us to verify if lack of expression of functional
BTK in XLA patients might be bypassed by alternative mechanisms able to activate Ca2+ mobi-
lization or by Ca2+-independent mechanisms.
Phagocytosis. To verify the independence of monocytes phagocytosis by Ca2+ mobiliza-
tion [36], in XLA and HD we used the calcium chelator BAPTA-AM. Data confirmed that
after calcium chelation the phagocytosis did not changed (Fig 9A and 9B). The independence
of phagocytic process by Ca2+ mobilization was observed also in PMN (Fig 9C and 9D).
Oxidative burst. E. coli-induced oxidative burst by monocytes was more inhibited by cal-
cium chelation in HD than XLA (Fig 10A). The average reduction in XLA was about 50% (Fig
10B) while in HD was about 75% (Fig 10C). This finding suggests that in XLA patients the
Ca2+ mobilization required for the ROS production was necessary but less critical than in HD.
Also in PMN, BAPTA-AM induced a mild reduction of the E. coli-induced oxidative burst in
Fig 9. Monocytes and PMN phagocytosis—Ca2+ chelation. Whole blood samples were pre-treated with 100 μM of the
calcium chelator BAPTA-AM for 30 min and incubated in a water bath for 20 min at 37˚C with opsonized E. coli (1-2x109/
ml). The conversion of DHR 123 to R 123 was used to evaluate the intracellular ROS production. FSC and SSC
characteristics were used to identify the monocytes population. A regular phagocytosis was observed on monocytes and
PMN from HD and XLA even after calcium chelation demonstrating that the process is Ca2+independent. Results are
expressed as Mean Fluorescence Intensity. Histograms denote mean values and bars standard deviation. In (A and B) are
shown monocytes and in (C and D) PMN phagocytosis of representative XLA patient: black peak BAPTA-AM(-) and gray
peak BAPTA-AM(+).
https://doi.org/10.1371/journal.pone.0175961.g009
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XLA than HD (Fig 11A). The average reduction in XLA was about 50% (Fig 11B), while in HD
was about 75% (Fig 11C). By contrast, the Ca2+ chelation did not affect PMN oxidative burst
induced by PMA. Indeed, PMA induced a normal oxidative burst even when calcium was che-
lated (Fig 11D and 11F). This observation was expected since the PMA induces the ROS pro-
duction through a direct binding to protein kinase C (PKC) [46, 47].
Discussion
Mutations in BTK gene lead to an impaired B cell development resulting in absent or very low
number of B-cells and profound hypogammaglobulinemia in patients affected by XLA [1, 2].
Previous studies on patients with XLA [7–9] showed the involvement of BTK in innate
immune cell responses [48] and its role in human DC responses upon TLR9 engagement [49].
Moreover, studies on the immune function of XLA patients who lack functional BTK might
also provide information concerning the consequences of drugs acting as BTK inhibitors on
innate immunity of patients under these new treatments [50–54].
In this study, we show that monocyte and PMN from XLA patients normally express those
receptors involved in their activation, suggesting that they did not exhibit an altered activation
status. Despite the lack of BTK, monocytes and PMN rapidly overexpressed surface receptors
after stimulation with opsonized bacteria, suggesting that BTK could be dispensable or
Fig 10. Monocytes oxidative burst—Ca2+ chelation. Whole blood samples were pre-treated with 100 μM of the calcium chelator
BAPTA-AM for 30 min and incubated in a water bath for 20 min at 37˚C with opsonized E. coli (1-2x109/ml) and PMA (1.62 mM). The
conversion of DHR 123 to R 123 was used to evaluate the intracellular ROS production. FSC and SSC characteristics were used to
identify the monocytes population. (A) BAPTA-AM treatment cause a stronger reduction of E. coli-induced oxidative burst in HD than
XLA (▪▪▪p = 0.003). (A) The average reduction in HD was about 75% (▪p = 0.01) and it was about 50% in XLA patients
(▪▪p = 0.02). (D) BAPTA-AM did not affect the oxidative burst induced by PMA both HD and XLA patients. Results are expressed as
Mean Fluorescence Intensity. Histograms denote mean values and bars standard deviation. Statistical significance, indicated as p
value, was determined by the nonparametric Mann-Whitney test and Wilcoxon Signed Rank test. (B and C) It shown monocytes E.
coli-induced oxidative burst in a representative HD and XLA patient, black peak BAPTA-AM(-) and gray peak BAPTA-AM(+). (E and
F) It shown monocytes PMA-induced oxidative burst in a representative HD and XLA patient, black peak BAPTA-AM(-) and gray peak
BAPTA-AM(+).
https://doi.org/10.1371/journal.pone.0175961.g010
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bypassed in pathways triggered by FcγR clustering. Moreover, the study of the oxidative burst
and phagocytosis provided us information on the killing ability of innate immune cells in XLA
patients. In agreement with previous studies [44, 55], the phagocytosis and respiratory burst
induced through FcγR were preserved in monocytes and PMN confirming that the BTK kinase
activity is bypassed during the engagement of FcγR. These results also suggested that BTK
might not be essential for Ca2+ mobilization, an event normally required for ROS production.
Indeed, activated BTK induce a rapid Ca2+ release trough the phosphorylation of PLCγ2 that
generates diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3). IP3 binds IP3 receptors
and activates Ca2+-release channels on the endoplasmic reticulum (ER), triggering the calcium
flux [14, 56]. Both DAG and Ca2+ are able to activate the PKC, the enzyme responsible for
NADPH oxidase activation [46, 47]. The lack of BTK in XLA patients might be bypassed by an
efficient activation of PLCγ2 performed by Syk, as we show in Fig 12 [57]. In monocytes,
PLCγ2 is activated by FcγRI and FcγRIIA whereas in neutrophils the engagement of FcγRIIA
is sufficient for its activation [57]. Moreover, we found that BAPTA-AM exerted a greater inhi-
bition of the oxidative burst in HD than XLA, suggesting that ROS production in XLA patients
is less dependent on Ca2+ mobilization. It is possible that the residual ability to produce ROS
in XLA patients depend on a greater efficacy of DAG-dependent stimulation of PKC, an
enzyme normally maintained in an inactive conformation [58–60]. In agreement with this
finding, we showed that the Ca2+ chelator BAPTA-AM did not affect the ROS production
when PMA was provided as stimulus since phorbol esters are able to bind PKC in the same
Fig 11. PMN oxidative burst—Ca2+ chelation. Whole blood samples were pre-treated with 100 μM of the calcium chelator
BAPTA-AM for 30 min and incubated in a water bath for 20 min at 37˚C with opsonized E. coli (1-2x109/ml) and PMA (1.62 mM). The
conversion of DHR 123 to R 123 was used to evaluate the intracellular ROS production. FSC and SSC characteristics were used to
identify the PMN population. (A) BAPTA-AM treatment cause a stronger reduction of E. coli-induced oxidative burst in HD than XLA
(▪▪▪p = 0.003). (A) The average reduction in HD was about 75% (▪p = 0.01) and it was about 50% in XLA patients (▪▪p = 0.02).
(D) BAPTA-AM did not affect the oxidative burst induced by PMA both HD and XLA patients. Results are expressed as Mean
Fluorescence Intensity. Histograms denote mean values and bars standard deviation. Statistical significance, indicated as p value,
was determined by the nonparametric Mann-Whitney test and Wilcoxon Signed Rank test. (B and C) It shown PMN E. coli-induced
oxidative burst in a representative HD and XLA patient, black peak BAPTA-AM(-) and gray peak BAPTA-AM(+). (E and F) It shown
PMN PMA-induced oxidative burst in a representative HD and XLA patient, black peak BAPTA-AM(-) and gray peak BAPTA-AM(+).
https://doi.org/10.1371/journal.pone.0175961.g011
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binding site of DAG and thus inducing kinase activation [46, 47, 61]. Our observations are
supported by others studies reporting different pathways for Ca2+ mobilization [62–64] and
are also in agreement with the conclusions made by Ren et al [36] who hypothesized that the
inhibition of BTK kinase activity within a whole organism could have limited effects on the
FcγR-mediated processes. Our results are also in agreement with the study of Marron et al [44]
who showed a ROS production not augmented or compromised in neutrophils from patients
with XLA but in contrast with the results of Honda et al [9] who described an excessive ROS
production. One possibility that could explain these discrepancies is related to differences in
the methods of PMN collection and in the stimuli used during the experimental procedures, in
that we used a more physiological stimulus such as the opsonized E. coli or a higher PMA con-
centration. Moreover, we found that the FcγR-mediated phagocytosis performed by mono-
cytes and PMN was fully functional and it remained unaltered when monocytes and PMN
were pre-treated with a Ca2+ chelator, confirming the independence of phagocytosis by Ca2+
mobilization [65–68]. Thus, the BTK kinase activity or the Ca2+ mobilization downstream
BTK did not appear to be required for this process, as previously shown using a BTK inhibitor
[36].
Fig 12. Schematic representation of signaling pathways for phagocytosis and oxidative burst. As a
result of FcγR clustering, two separate pathways lead to phagocytosis, through a calcium independent way, or
to the oxidative burst in a calcium dependent manner. Syk induce the activation of Vav and the downstream
signaling that lead to the phagocytosis process. The main pathway for the activation of the oxidative burst
consist in the activation of Btk by Syk and the consequent phosphorylation of PLCγ2. PLCγ2 activated
produce DAG and IP3 from PIP3. DAG directly activate PKC while IP3 bind IP3R on endoplasmic reticulum
inducing Ca2+ mobilization that lead to PKC activation and finally to the oxidative burst. The lack of BTK in
XLA patients is effectively bypassed by the direct stimulation of PLCγ2 by Syk. The inhibition of Ca2+
mobilization by BAPTA-AM strongly reduce the oxidative burst. PMA is able to bind PKC to the same binding
site of DAG and bypass both the production of DAG and the calcium flux from endoplasmic reticulum.
https://doi.org/10.1371/journal.pone.0175961.g012
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The only abnormality found was the overexpression of CD66b, suggesting an hyperactiva-
tion status of PMN. CD66b is able to stimulate neutrophils and its crosslinking is able to
induce the secretion of preformed interleukin-8 (IL-8) [69]. The dosage of the IL-8 in the
plasma of patients was normal in unstimulated condition. After stimulation with E. coli, IL-8
showed a rapid increase, suggesting that PMN of XLA patients effectively respond to opso-
nized bacteria in terms of cytokine secretion. However, our data show that the altered expres-
sion of CD66b on PMN surface did not correlate with IL-8 and elastase secretion and
therefore it needs to be better clarified.
Also others functions involved in functionality of PMN, such as migration and elastase
degranulation, were well preserved in XLA patients, confirming that all the fundamental steps
involved in PMN killing ability were fully functional.
XLA patients received a long-life substitutive treatment with polyvalent IgG as a prophy-
laxis against infections [20, 21]. IVIg infusions could exert an anti-inflammatory function,
even if administrated at replacement dosages, acting on monocytes as we recently showed in
monocyte from CVID [23]. Interestingly, in line with our previous observation, XLA patients
showed an increased percentage of intermediate monocyte, possibly caused by their inflamma-
tory condition. This observation suggest that a greater frequency of intermediate monocytes
could be a common feature of different PAD. The prompt reduction of the number of inter-
mediate monocytes observed after IVIg is in line with the observation made in CVID patients
[23] confirming the normalizing effect of IVIg infusion on monocytes. In addition, we show
that the in vivo IVIg administration did not affect the expression of any surface receptors con-
sidered. Consistent with our previous study [23], we show that IVIg administration induced a
decrease of monocytes’ oxidative burst and phagocytosis. We hypothesize that the transient
binding of IVIg to FcγR might reduce the availability of monocyte receptors for the binding
with opsonized E. coli, resulting in a slight reduction of phagocytosis and consequently in a
reduced ROS production.
In summary, the lack of BTK kinase activity in XLA did not affect monocytes and PMN
functions. IVIg infusion exerted a dampening effect on monocytes compartment by reducing
the pro-inflammatory subset and by reducing their killing ability.
Supporting information
S1 Fig. Identification of PMN population. Whole blood samples were treated to lyse red
blood cells for 20 minutes at room temperature and washed twice. White cells were suspended
in ice-cold PBS and stained at 4˚C for 30 min with CD15 fluorochrome-labeled antibody. Sam-
ples were washed, suspended in ice-cold PBS and analyzed by flow cytometry. PMN were iden-
tified by Side Scatter (SSC) and CD15 fluorochrome-labeled antibody. CD15 was used as a
specific marker of neutrophils. A representative XLA patient is shown A and B.
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S2 Fig. Correlation between oxidative burst and phagocytosis before and after IVIg.
Figure shows a positive correlation between oxidative burst and phagocytosis confirming the
dependence of oxidative burst process from phagocytosis. Correlation was calculated by
means of linear regression analysis.
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S1 Table. Demographic and clinical data of patients XLA. Serum IgG, IgA and IgM values
refer to pre-infusion levels. M, male. COPD: Chronic obstructive pulmonary disease.
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